Press Release

Sanofi announces changes to its Executive Committee - Seite 2

Paul Hudson
Chief Executive Officer, Sanofi
“These new appointments, a healthy mix of internal promotions and a newcomer to Sanofi, bring three highly qualified global leaders with new insights and world-class expertise in their field. I am confident in their capacity to inspire our people, execute and deliver on our strategy and support our ambition to be an innovative, inclusive and scientifically driven leader.
On the science front, we have a bold strategy of first or best-in-class medicines and vaccines to fuel the growth of our company for the years to come. With almost 80 programs in clinical development and expecting to see the results of 27 readouts of early and mid-stage molecules over the next year, I am extremely pleased to see Houman Ashrafian joining our company. He brings a wealth of expertise as a scientist and in bringing high value transformational medicines from discovery to market. With Houman’s leadership and deep understanding of science, we aspire to make our R&D transformation sustainable. This is what we were aiming for when we laid out our strategy in 2019. With 5 positive read-outs in the first six months of 2023 only, including Dupixent in COPD, our commitment to Sanofi’s scientifically-driven roadmap couldn’t be any stronger”.

Houman Ashrafian – Executive Vice President, Head of R&D
Houman joins from SV Health Investors where he is Managing Partner of the global private equity and venture capital investment platform which has a special focus on biotechnology, healthcare growth equity, and medtech. He has a robust track record in building high value, successful companies in the healthcare space, that brought transformational medicines from discovery to market: he co-founded and chaired the biotechs Alchemab Therpeutics, Dualitas, Enara Bio, Mestag Therpeutics, Sitryx and Trex Bio. He was also member of the boards of Imbria, Prilenia and Therini Bio. Previously, he was Vice President and head of the Clinical Science Group at UCB with a main focus on precision medicine strategies and early clinical activities across the R&D portfolio. He also co-founded Cardiac Report, a cardiac services company, Heart Metabolics, Catamaran Bio, as well as Weatherden, a boutique clinical consultancy.